{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:17:02Z","timestamp":1787930222668,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13193-023-01775-z","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:01:15Z","timestamp":1685937675000},"page":"784-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center"],"prefix":"10.1007","volume":"14","author":[{"given":"Biswajit","family":"Dash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Shylasree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Rekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Gulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Sable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"2","key":"1775_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","volume":"120","author":"MA Vineyard","year":"2011","unstructured":"Vineyard MA et al (2011) Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol 120(2):229\u2013232. https:\/\/doi.org\/10.1016\/j.ygyno.2010.10.033","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1775_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica A et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496\u2013504. https:\/\/doi.org\/10.1097\/00000478-200404000-00009","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1775_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/ANNONC\/MDX010","volume":"28","author":"J McGee","year":"2017","unstructured":"McGee J et al (2017) Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol 28(4):702\u2013710. https:\/\/doi.org\/10.1093\/ANNONC\/MDX010","journal-title":"Ann Oncol"},{"issue":"2","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","volume":"143","author":"A Kaldawy","year":"2016","unstructured":"Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA (2016) Low-grade serous ovarian cancer: a review. Gynecol Oncol 143(2):433\u2013438. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.320","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1775_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13244-021-01004-7","volume":"12","author":"S Amante","year":"2021","unstructured":"Amante S, Santos F, Cunha TM (2021) Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists. Insights Imaging 12(1):60. https:\/\/doi.org\/10.1186\/s13244-021-01004-7","journal-title":"Insights Imaging"},{"issue":"12","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19(12):1680\u20131687. https:\/\/doi.org\/10.1016\/S1470-2045(18)30566-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"1775_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/CNCY.21219","volume":"120","author":"N Sneige","year":"2012","unstructured":"Sneige N, Thomison JB, Malpica A, Gong Y, Ensor J, Silva EG (2012) Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome. Cancer Cytopathol 120(4):238\u2013244. https:\/\/doi.org\/10.1002\/CNCY.21219","journal-title":"Cancer Cytopathol"},{"issue":"3","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/IJPM.IJPM_858_19","volume":"63","author":"B Rekhi","year":"2020","unstructured":"Rekhi B et al (2020) Evaluation of cell blocks from effusion specimens in gynecologic oncopathology: an experience of 220 cases, diagnosed at a tertiary cancer referral center. Indian J Pathol Microbiol 63(3):427. https:\/\/doi.org\/10.4103\/IJPM.IJPM_858_19","journal-title":"Indian J Pathol Microbiol"},{"key":"1775_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejogrb.2020.11.021","volume":"256","author":"IA Voutsadakis","year":"2021","unstructured":"Voutsadakis IA (2021) A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma. Eur J Obs Gynecol Reprod Biol 256:172\u2013178","journal-title":"Eur J Obs. Gynecol Reprod Biol."},{"issue":"1","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1746-1596-8-21","volume":"8","author":"D Sundov","year":"2013","unstructured":"Sundov D et al (2013) P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS\/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 8(1):1. https:\/\/doi.org\/10.1186\/1746-1596-8-21","journal-title":"Diagn Pathol"},{"issue":"3","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/J.YGYNO.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski JP et al (2016) Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 140(3):457\u2013462. https:\/\/doi.org\/10.1016\/J.YGYNO.2016.01.022","journal-title":"Gynecol Oncol"},{"issue":"9 Suppl 3","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","volume":"24","author":"C Gourley","year":"2014","unstructured":"Gourley C et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer 24(9 Suppl 3):S9\u2013S13. https:\/\/doi.org\/10.1097\/IGC.0000000000000257","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/IJGC-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti A et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30(11):1657\u20131664. https:\/\/doi.org\/10.1136\/IJGC-2020-001640","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/J.YGYNO.2007.11.013","volume":"108","author":"KM Schmeler","year":"2008","unstructured":"Schmeler KM et al (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510\u2013514. https:\/\/doi.org\/10.1016\/J.YGYNO.2007.11.013","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1775_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672\u2013705. https:\/\/doi.org\/10.1093\/annonc\/mdz062","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","volume":"27","author":"DM Gershenson","year":"2016","unstructured":"Gershenson DM (2016) Low-grade serous carcinoma of the ovary or peritoneum. Ann Oncol 27(Supplement 1):i45\u2013i49. https:\/\/doi.org\/10.1093\/annonc\/mdw085","journal-title":"Ann Oncol"},{"issue":"1","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/J.YGYNO.2009.03.001","volume":"114","author":"DM Gershenson","year":"2009","unstructured":"Gershenson DM et al (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48\u201352. https:\/\/doi.org\/10.1016\/J.YGYNO.2009.03.001","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC (2017) Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103\u20131111. https:\/\/doi.org\/10.1200\/JCO.2016.71.0632","journal-title":"J Clin Oncol"},{"issue":"3","key":"1775_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.YGYNO.2012.02.037","volume":"125","author":"DM Gershenson","year":"2012","unstructured":"Gershenson DM et al (2012) Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125(3):661\u2013666. https:\/\/doi.org\/10.1016\/J.YGYNO.2012.02.037","journal-title":"Gynecol Oncol"},{"issue":"13","key":"1775_CR20","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.3390\/CANCERS13133114","volume":"13","author":"W Ceelen","year":"2021","unstructured":"Ceelen W, Demuytere J, de Hingh I (2021) Hyperthermic intraperitoneal chemotherapy: a critical review. Cancers 2021 13(13):3114. https:\/\/doi.org\/10.3390\/CANCERS13133114","journal-title":"Cancers 2021"},{"issue":"3","key":"1775_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/nejmoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230\u2013240. https:\/\/doi.org\/10.1056\/nejmoa1708618","journal-title":"N Engl J Med"},{"issue":"1","key":"1775_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(05)70539-8","journal-title":"Lancet Oncol"},{"issue":"1","key":"1775_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/J.YGYNO.2017.01.027","volume":"145","author":"HJ Dalton","year":"2017","unstructured":"Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM (2017) Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecol Oncol 145(1):37\u201340. https:\/\/doi.org\/10.1016\/J.YGYNO.2017.01.027","journal-title":"Gynecol Oncol"},{"issue":"32","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk BJ et al (2020) MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol 38(32):3753\u20133762. https:\/\/doi.org\/10.1200\/JCO.20.01164","journal-title":"J Clin Oncol"},{"key":"1775_CR25","doi-asserted-by":"publisher","unstructured":"Gershenson DM, Gourley C, Paul J (2020) \u2018MEK inhibitors for the treatment of low-grade serous ovarian cancer: expanding therapeutic options for a rare ovarian cancer subtype\u2019. 38(32):3731\u20133734.\u00a0https:\/\/doi.org\/10.1200\/JCO.20.02190","DOI":"10.1200\/JCO.20.02190"},{"issue":"2","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/J.YGYNO.2017.05.019","volume":"146","author":"I Mert","year":"2017","unstructured":"Mert I et al (2017) Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecol Oncol 146(2):319\u2013326. https:\/\/doi.org\/10.1016\/J.YGYNO.2017.05.019","journal-title":"Gynecol Oncol"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-023-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-023-01775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-023-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T11:07:05Z","timestamp":1704366425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-023-01775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1007\/s13193-023-01775-z","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}